Greccas

Greccas is a prescription medication that contains the active ingredient ticagrelor. It is supplied as an oral dosage form, with the specific strength not disclosed, and is marketed in the European Union. Ticagrelor belongs to the P2Y12 receptor antagonist class and works as an antiplatelet agent to help reduce the risk of clot‑related cardiovascular events.

Greccas is indicated for patients who need antiplatelet therapy to lower the chance of thrombotic complications. It is commonly prescribed in the following clinical situations:

- Prevention of thrombotic events in individuals with acute coronary syndrome (ACS). - Reduction of cardiovascular death, myocardial infarction, and stroke risk after an ACS event. - Use as part of dual antiplatelet therapy following percutaneous coronary intervention (PCI). - Management of patients with a high risk of recurrent ischemic events. - Adjunct therapy in selected patients with stable coronary artery disease when advised by a physician.

Ticagrelor, the active component of Greccas, may cause a range of side effects. These are generally categorized by frequency and severity.

Common: - Shortness of breath or dyspnea, often mild to moderate. - Headache, which may be intermittent. - Nausea or gastrointestinal discomfort. - Minor bruising or bleeding from cuts. - Dizziness, especially when standing quickly.

Serious: - Severe or uncontrolled bleeding, including intracranial hemorrhage. - Allergic reactions such as rash, itching, or swelling. - Liver enzyme elevations indicating possible hepatic injury. - Thrombotic thrombocytopenic purpura (TTP) in rare cases. - Sudden drop in blood pressure (hypotension).

Before starting Greccas, certain health considerations should be reviewed with a healthcare professional. Important precautions include:

- History of active bleeding, recent surgery, or hemorrhagic stroke. - Severe liver impairment or elevated liver enzymes. - Concomitant use of strong CYP3A inhibitors or inducers. - Known hypersensitivity to ticagrelor or any excipients. - Pregnancy, breastfeeding, or planning to become pregnant. - Renal dysfunction that may affect drug clearance. - Monitoring for signs of dyspnea or unexplained shortness of breath.

Greccas can interact with other medicines, affecting its safety and effectiveness. Interactions are grouped by the level of risk.

Avoid: - Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk. - Anticoagulants like warfarin or direct oral anticoagulants without dose adjustment.

Use with caution: - CYP3A4 inducers (e.g., rifampin, carbamazepine) that may lower ticagrelor levels. - Other antiplatelet agents (e.g., aspirin, clopidogrel) when combined therapy is required. - Proton pump inhibitors that may affect absorption. - Herbal supplements such as St. John’s wort that influence CYP enzymes.